Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT-I with Doxorubicin and Ifosfamide in Advanced Soft Tissue Sarcoma
NCT06277154Phase 2Recruiting
- Sponsor
- HRYZ Biotech
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MASCT-I in soft tissue sarcoma (STS), sponsored by HRYZ Biotech. Started Feb 2024; status: recruiting.
02
Drugs
MASCT-I
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06277154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277154.